Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Harpoon Therapeutics stock

Own Harpoon Therapeutics stock in just a few minutes.

Posted

Fact checked

Harpoon Therapeutics, Inc is a biotechnology business based in the US. Harpoon Therapeutics shares (HARP) are listed on the NASDAQ and all prices are listed in US Dollars. Harpoon Therapeutics employs 76 staff and has a trailing 12-month revenue of around USD$9.7 million.

How to buy shares in Harpoon Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Harpoon Therapeutics. Find the stock by name or ticker symbol: HARP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Harpoon Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Harpoon Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Harpoon Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Harpoon Therapeutics share price

Use our graph to track the performance of HARP stocks over time.

Harpoon Therapeutics shares at a glance

Information last updated 2020-10-19.
52-week range USD$10.27 - USD$25.02
50-day moving average USD$16.0324
200-day moving average USD$15.1596
Wall St. target price USD$31.22
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.049

Buy Harpoon Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Harpoon Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Harpoon Therapeutics financials

Revenue TTM USD$9.7 million
Gross profit TTM USD$-35,815,000
Return on assets TTM -20.35%
Return on equity TTM -57.02%
Profit margin 0%
Book value $2.866
Market capitalisation USD$407.3 million

TTM: trailing 12 months

Shorting Harpoon Therapeutics shares

There are currently 880,585 Harpoon Therapeutics shares held short by investors – that's known as Harpoon Therapeutics's "short interest". This figure is 6.5% up from 826,570 last month.

There are a few different ways that this level of interest in shorting Harpoon Therapeutics shares can be evaluated.

Harpoon Therapeutics's "short interest ratio" (SIR)

Harpoon Therapeutics's "short interest ratio" (SIR) is the quantity of Harpoon Therapeutics shares currently shorted divided by the average quantity of Harpoon Therapeutics shares traded daily (recently around 266037.76435045). Harpoon Therapeutics's SIR currently stands at 3.31. In other words for every 100,000 Harpoon Therapeutics shares traded daily on the market, roughly 3310 shares are currently held short.

However Harpoon Therapeutics's short interest can also be evaluated against the total number of Harpoon Therapeutics shares, or, against the total number of tradable Harpoon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Harpoon Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Harpoon Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.083% of the tradable shares (for every 100,000 tradable Harpoon Therapeutics shares, roughly 83 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Harpoon Therapeutics.

Find out more about how you can short Harpoon Therapeutics stock.

Harpoon Therapeutics share dividends

We're not expecting Harpoon Therapeutics to pay a dividend over the next 12 months.

Harpoon Therapeutics overview

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site